Trial Profile
A Phase II study of DJ-927 administered orally once every three weeks as second line therapy to subjects with locally advanced or metastatic non-small cell lung cancer (NSCLC) after failure of a platinum-based non-taxane regimen
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 16 May 2011
Price :
$35
*
At a glance
- Drugs Tesetaxel (Primary)
- Indications Non-small cell lung cancer
- Focus Adverse reactions; Pharmacokinetics; Therapeutic Use
- Sponsors Daiichi Pharmaceutical
- 16 May 2011 New trial record